💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Immunomedics, Inc. (IMMU)
« Back to company indexIMMU Chatter Timeline
Stock Ticker for IMMU
Most Active Tweeters for IMMU
| User | Tweets |
|---|---|
| @askwarrenbuffet | 3 |
| @biotechradar_eu | 2 |
| @Franca_ole | 2 |
| @lblegend33 | 1 |
| @redacre | 1 |
Recent Tweets for IMMU
 |
@lblegend33 @redacre $immu? Didn’t that get BO while back? April 14th 2021, 8:04pm |
 |
@Franca_ole FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial #cancer #Trodelvy $IMMU $GILD https://t.co/sf5MnkCPeP April 14th 2021, 9:04am |
 |
@biotechradar_eu Immunicum $IMMU Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai https://t.co/zvuXJGkhwA April 14th 2021, 8:04am |
 |
@jq1234t @bigpharmaguy Don’t think that’s the right comparison. $IMMU FDA AA approval great but bigger driver was huge succe… https://t.co/yxriRtxLp0 April 9th 2021, 4:04pm |
 |
@JosephRamelli RT @bigpharmaguy: Probably an unpopular take but $FGEN here gives me shades of $IMMU a year ago. Both had separate issues and were in revie… April 9th 2021, 2:04pm |
 |
@bigpharmaguy Probably an unpopular take but $FGEN here gives me shades of $IMMU a year ago. Both had separate issues and were in… https://t.co/5wFFhIZZSS April 9th 2021, 1:04pm |
|
@Franca_ole #FDA grants regular approval to #sacituzumab govitecan for triple-negative breast cancer https://t.co/OWnOVz2XdZ $IMMU $CYDY #TNBC April 7th 2021, 10:04pm |
|
@biotechradar_eu Immunicum $IMMU Announces Investor Event and Conference Participation for April https://t.co/PAlAhew3ih April 7th 2021, 9:04am |
 |
@askwarrenbuffet $HMBL CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/a4PRNFbtdS April 6th 2021, 8:04pm |
 |
@redacre Biotech/HC New or revisited 52-Week Lows: $ACAD $IMMU April 6th 2021, 8:04pm |
 |
@stockmarkettile @LemonyS14621590 @Discover_Divs And their acquisition of $IMMU, how’s that going? April 5th 2021, 11:04pm |
|
@askwarrenbuffet $CSOC CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/zPffnBiSQL April 3rd 2021, 7:04pm |
 |
@MimedxGroupie A threat for $IMMU said the paid $CYDY moron. https://t.co/qeiOXRvOVc https://t.co/eN6Lox6LPP April 2nd 2021, 9:04am |
|
@askwarrenbuffet $CSOC CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/njguYyveX0 April 1st 2021, 4:04am |
|
@redacre Biotech/HC New or revisited 52-Week Lows: $GEN $IMMU March 31st 2021, 8:03pm |
|
@askwarrenbuffet $ATMH CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/61h3KPi3P5 March 28th 2021, 2:03am |
 |
@haodongvli $XBI you have to go shopping when people think it is a landfill, as a matter of fact, it is a gold mine! $IMMU… https://t.co/gkMTk8aQbO March 26th 2021, 4:03pm |
 |
@DesertDweller93 Hard to believe $sgen market cap getting close to where $immu was bought out at. sgen with its approved drugs plus… https://t.co/BhMk3kr7AG March 24th 2021, 4:03pm |
|
@askwarrenbuffet $COG CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/sx0YIgY535 March 22nd 2021, 11:03pm |
|
@askwarrenbuffet $LEAS CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/HT5YVgyQlt March 19th 2021, 5:03am |
|
@askwarrenbuffet $RXMD CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/nZWeGN7Gc7 March 18th 2021, 2:03am |
 |
@eyemightbewrong @LSValue I actually looked at $immu with Shkreli traded emails in prison ha and he and I were both like how is this… https://t.co/9BO1oiZLV8 March 17th 2021, 6:03am |
 |
@MayWatchTooMuch @TheLioncom OK, I am in too. Always looking for my next $IMMU March 16th 2021, 5:03am |
|
@askwarrenbuffet $CRM CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/YCM2fzNm9L March 16th 2021, 3:03am |
|
@askwarrenbuffet $CLSK CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/aDbTNrJso6 March 13th 2021, 3:03am |
 |
@Panacea_Trading $ACAD shades of $IMMU? Or is this something more.. March 9th 2021, 2:03pm |
 |
@hcgeneralist I remember when $IMMU got a CRL for manufacturing reasons. A while later I talked with a person that knew them well… https://t.co/whAxRIlhvc March 9th 2021, 12:03pm |
 |
@sbwcws UBS pharmaceuticals analysts to hold an analyst/industry conference call $AZN $IMMU March 8th 2021, 4:03pm |
|
@askwarrenbuffet $HQGE CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/cVVcVslasl March 4th 2021, 1:03am |
|
@biotechradar_eu Immunicum $IMMU Announces Appointment of Jeroen Rovers as Chief Medical Officer https://t.co/xKKHlLdHgi March 1st 2021, 7:03am |
|
@askwarrenbuffet $CBDD CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/2DnFi6444p February 26th 2021, 5:02am |
|
@askwarrenbuffet $NPHC CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/3ujgTRrTUZ February 25th 2021, 2:02am |
|
@biotechradar_eu Immunicum $IMMU Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney C… https://t.co/ZKDrT2azOS February 22nd 2021, 8:02am |
|
@biotechradar_eu Immunicum $IMMU Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal… https://t.co/cp3WBqDziZ February 19th 2021, 7:02am |
|
@askwarrenbuffet $PVDG CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/eW0ylwZpdC February 19th 2021, 2:02am |
|
@biotechradar_eu Immunicum $IMMU Announces Year-End Results 2020 https://t.co/pwroL38jI9 February 18th 2021, 10:02am |
 |
@PaulTorresCohen Paul Torres-Cohen $IMMU February 15th 2021, 2:02pm |
 |
@BurchetJohn @austinfrank Lol. Like early 2020 when GS put a PT on $IMMU at $5.30. My little stake of 70k shares were settled Oc… https://t.co/kzUlZqVzpx February 14th 2021, 12:02pm |
 |
@Traderofstocks1 $IMMU https://t.co/ht1eyRUYPn February 12th 2021, 7:02pm |
|
@askwarrenbuffet $TGODF CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/3d1aINYMYT February 12th 2021, 1:02am |
 |
@sunrgu @Sanctuary_Bio Only the best deal they ever made in recent years is $IMMU February 10th 2021, 2:02pm |
 |
@trademarktrader TRODELVY is under file for trademark by IMMUNOMEDICS, INC. https://t.co/C0jEDoveSP #TRODELVY $IMMU https://t.co/AqqzAyxSGk February 10th 2021, 1:02pm |
 |
@TimCarmichael3 $TGTX this situation mirrors what I witnessed with $IMMU —shepherd your drugs through the FDA, build up the sales f… https://t.co/DOvSQsoWfG February 5th 2021, 8:02pm |
 |
@YGOUCHA @Biohazard3737 And $IMMU prior February 5th 2021, 7:02pm |
 |
@Sanctuary_Bio RT @adar170: $IMMU Trodelvy 49 million https://t.co/RoIZQUm9B8 February 4th 2021, 9:02pm |
|
@sunrgu $GILD $IMMU Trodelvy® (sacituzumab govitecan-hziy 180 mg) sales for the fourth quarter and full year 2020, includi… https://t.co/cFipMhdaBs February 4th 2021, 9:02pm |
 |
@adar170 $IMMU Trodelvy 49 million https://t.co/RoIZQUm9B8 February 4th 2021, 9:02pm |
 |
@MSS1992BIO @JacobPlieth Should have bought $immu when they had the chance February 4th 2021, 9:02am |
|
@askwarrenbuffet $TXHE CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/zyzEAWHmXa February 4th 2021, 1:02am |
|
@askwarrenbuffet $APYP CEO To Be Featured On "CNNMoney" Segment Next Week Gaining Extensive Exposure https://t.co/Mv3xmUJu9A $IMMU… https://t.co/Oyd8FrKPCK February 2nd 2021, 1:02am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
